ACTRN12606000423516招募中1 期
A pilot study of the pharmacokinetics, affect on Smoking Urges, and acceptability of a novel nicotine inhaler in smokers
Professor Julian Crane0 个研究点目标入组 10 人开始时间: 2006年10月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Smoked >10 cigarettes per day.
排除标准
- •Recent use of other nicotine replacement therapy such as bupropion; cardiovascular, psychiatric history of note.
研究者
相似试验
进行中（未招募）
不适用
A Pilot Pharmacodynamic/Pharmacokinetic Study of SalmeterolXinofoate as a Dry Powder in Combination with Fluticasone in Patients with Asthma for Dose-Scale Bronchodilator Model Development.AsthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2010-018712-32-GBOriel Therapeutics Inc30
进行中（未招募）
不适用
Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infectionshospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection.MedDRA version: 14.1Level: LLTClassification code 10021804Term: Infection bacterialSystem Organ Class: 100000004862EUCTR2013-001900-13-Outside-EU/EEAAstraZeneca AB32
进行中（未招募）
1 期
A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy - Pharmacokinetics of switching from efavirenz to maravirocHIVEUCTR2009-014694-40-GB12
进行中（未招募）
1 期
A Phase I study to investigate the pharmacokinetics and ECG effects of two single ascending doses of linaprazan glurate given as oral tablets to healthy subjectsErosive Gastroesophageal Reflux Disease (eGERD)MedDRA version: 20.1Level: LLTClassification code: 10017924Term: Gastroesophageal reflux Class: 10017947CTIS2024-516261-36-00Cinclus Pharma Holding AB (publ)63
已完成
1 期
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Selgantolimod upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor AntagonistHepatitis BOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInfection - Other infectious diseasesACTRN12620001019998Gilead Sciences50